$0.30
1.57% yesterday
Nasdaq, Nov 15, 10:18 pm CET
ISIN
US92731L1061
Symbol
VINC
Sector
Industry

Vincerx Pharma Inc Stock price

$0.30
-0.08 22.35% 1M
-0.45 60.56% 6M
-0.89 75.00% YTD
-0.48 61.98% 1Y
-12.21 97.64% 3Y
-9.06 96.84% 5Y
-9.06 96.84% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.00 1.57%
ISIN
US92731L1061
Symbol
VINC
Sector
Industry

Key metrics

Market capitalization $9.90m
Enterprise Value $1.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.02
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-28.17m
Free Cash Flow (TTM) Free Cash Flow $-27.97m
Cash position $10.17m
EPS (TTM) EPS $-1.03
P/E forward negative
Short interest 3.00%
Show more

Is Vincerx Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Vincerx Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vincerx Pharma Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Vincerx Pharma Inc forecast:

Buy
100%

Financial data from Vincerx Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.07 1.07
19% 19%
-
-1.07 -1.07
19% 19%
-
- Selling and Administrative Expenses 11 11
25% 25%
-
- Research and Development Expense 15 15
58% 58%
-
-27 -27
47% 47%
-
- Depreciation and Amortization 1.07 1.07
19% 19%
-
EBIT (Operating Income) EBIT -28 -28
46% 46%
-
Net Profit -27 -27
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vincerx Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vincerx Pharma Inc Stock News

Neutral
GlobeNewsWire
about one month ago
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology
Neutral
GlobeNewsWire
3 months ago
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024
Neutral
GlobeNewsWire
6 months ago
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC)

Company Profile

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed Hamdy, Raquel Izumi, Tom Thomas, Stuart Hwang, and John Byrd in 2018 and is headquartered in Palo Alto, CA.

Head office United States
CEO Ahmed Hamdy
Employees 42
Founded 2018
Website vincerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today